Week in Review: Working Toward a Bright Future in R&D

Week in Review: Working Toward a Bright Future in R&D

02.21.14 | By Kaelan Hollon

Despite the inevitable hurdles and roadblocks that arise throughout the R&D process, this past week we highlighted the medical breakthroughs aimed to improve the lives of patients around the world.

On Thursday, guest blogger Peter Huber, author of Cure in the Code and a Senior Fellow at the Manhattan Institute, wrote about advancements in technology and the impact that these advancements have on almost every aspect of pharmacology. He explained that micro-electromechanical laboratories can be used to better understand how diseases progress and how drugs can be more precisely administered to patients. Even with these new developments, Huber noted that the clinical implication of this technology, and the data it provides, are still relatively unknown. Ultimately, however, the molecular monitoring created through new technologies will pave the way for future developments and vastly improve the field of biopharmaceutical R&D and the lives of patients.    

The technological developments noted by Peter Huber are likely strengthened by the creation of new collaborative relationships within the R&D community. According to Peter Saltonstall, President and CEO of the National Organization for Rare Disorders (NORD), cooperation within the biopharmaceutical community has led to a greater awareness of, and investment in, orphan drug development. Saltonstall discussed Rare Disease Day on February 28 and how recognition of this day can lead to a greater understanding of the rare disease community. Through collaboration, the biopharmaceutical industry can build on existing progress and work toward the universally common goal of positively impacting the lives of patients and their families.

With so many promising opportunities on the horizon, the biopharmaceutical industry must also recognize institutional barriers that have the potential to halt progress. Industry concerns regarding India’s protectionist intellectual property (IP) policies have hindered innovation within the United States in the past and will continue to close doors for leading innovators around the world. Strong IP policies are essential to the productivity and growth needed for the development of new medicines  for patients.

This week has provided an exciting glimpse into the future of R&D and there is more to come. Check back often for more on what’s on the horizon and don't forget to read our Conversation forum each week where we ask experts to discuss subjects afflicting the medicine community and encourage you to share your thoughts on Facebook and Twitter.

 

Comments

Hide Comments

More On PhRMA — powered by PhRMApedia